Search Result

Isoforms Recommended:	K-Ras

Results for "

KRAS

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (1) Akt (4) Aminoacyl-tRNA Synthetase (1) AMPK (1) Antibiotic (2) Apoptosis (29) ATTECs (1) Autophagy (11) Biochemical Assay Reagents (1) c-Fms (1) Calcium Channel (3) Caspase (2) CDK (1) CRM1 (1) DNA/RNA Synthesis (1) Drug Derivative (1) Drug Intermediate (1) E3 Ligase Ligand-Linker Conjugates (4) EGFR (4) Epigenetic Reader Domain (2) ERK (19) Farnesyl Transferase (14) Ferroptosis (1) Fluorescent Dye (2) Fungal (1) GLUT (1) HSP (1) ICMT (4) IKK (1) Isotope-Labeled Compounds (4) JAK (1) Ligands for E3 Ligase (2) Ligands for Target Protein for PROTAC (5) MAPKAPK2 (MK2) (1) MDM-2/p53 (2) MEK (7) Mitosis (1) Molecular Glues (4) mTOR (4) NAMPT (1) NO Synthase (1) p38 MAPK (6) PARP (3) PDK-1 (1) PERK (6) Phosphatase (3) Phosphodiesterase (PDE) (11) PI3K (4) Polo-like Kinase (PLK) (1) PROTAC Linkers (6) PROTAC-Linker Conjugates for PAC (1) PROTACs (32) Protein Prenyltransferase (1) Raf (12) Ras (324) Reactive Oxygen Species (ROS) (1) Reference Standards (2) Ribosomal S6 Kinase (RSK) (2) SHP2 (2) Small Interfering RNA (siRNA) (4) SOS1 (27) Src (1) STING (3) STK33 (1) Target Protein Ligand-Linker Conjugates (7) Tie (1) ULK (1) VEGFR (3) Wnt (1) YAP (1) YB-1 (1) β-catenin (1) γ-Glutamyl Transferase (GGT) (1)
By Research Areas:	Cancer (406) Cardiovascular Disease (3) Infection (11) Inflammation/Immunology (6) Neurological Disease (1)
Click Chemistry:	Azide (3) Alkynes (19)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (2) siRNAs (4)

416

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-122914

KRAS inhibitor-3	Ras	Cancer
KRAS inhibitor-3 is an inhibitor of *KRAS* inhibitor. KRAS inhibitor-3 binds to WT and oncogenic KRAS mutants with high affinity (K_D: 0.28 μM for KRAS WT, 0.63 μM for KRAS G12C, 0.37 μM for KRAS G12D, 0.74 μM for KRAS Q61H). KRAS inhibitor-3 also disrupts interaction of KRAS with Raf .

HY-159652

KRAS inhibitor-31	Ras	Cancer
KRAS inhibitor-31 (compound 33) is a *KRAS* inhibitor, with K_D (SPR) values of 0.019 nM, 0.019 nM and 0.096 nM for KRas G12D, KRas G12C and KRas G12V, respectively .

HY-159476

KRAS inhibitor-26	Ras	Cancer
KRAS inhibitor-26 (compound 194a) is a potent KRAS G12V inhibitor (IC₅₀: ≤100 nM). KRAS inhibitor-26 can be used for cancer research .

HY-169311

KRAS inhibitor-37	Ras	Cancer
KRAS inhibitor-37 (compound 2) is a potent *KRAS* inhibitor with K_Ds of 0.004 nM, 0.041 nM, 0.019 nM and 0.144 nM for KRAS wild type, KRAS G12D, KRAS G12C and KRAS G12V by SPR binding assay, respectively. KRAS inhibitor-37 inhibits cell proliferation with IC₅₀s of <2 nM-14 nM for H358, SW620, PANC08.13 cells, respectively. KRAS inhibitor-37 has the potential for cancer research .

HY-153412

KRAS inhibitor-22	Ras	Cancer
KRAS inhibitor-22 (compound FB9/6B9) is a potent inhibitor of *K-Ras. KRAS* inhibitor-22 targets to Kras 4B(G12D) and (G12C), which can be used for cancer research .

HY-173329

KRAS inhibitor-41	Ras	Cancer
KRAS inhibitor-41 is an inhibitor of *KRAS* with IC₅₀ values of <0.01 μM for KRAS G12D and KRAS G12V. KRAS inhibitor-41 inhibits RAS mutant cell lines, GP2D (KRAS-G12D) and SW620 (KRAS-G12V). KRAS inhibitor-41 can be used in cancer research .

HY-176250

KRAS-IN-43	Ras ERK	Cancer
KRAS-IN-43 (Compound 9) is a pan-KRAS inhibitor with IC₅₀ values of 0.15 μM, 0.14 μM, and 0.47 μM against KRAS ^G12V, KRAS ^G12C and wild-type KRAS, respectively. KRAS-IN-43 disrupts the interaction between KRAS and cRAF, and inhibits ERK phosphorylation. KRAS-IN-43 is promising for research of KRAS mutation-related cancers (such as pancreatic cancer, colorectal cancer, and lung cancer) .

HY-162971

KRAS inhibitor-33	Ras	Cancer
KRAS inhibitor-33 (compound 115a) is an inhibitor of pyridopyrimidine kras (IC₅₀ ≤ 100nM) .

HY-174261

KRAS-IN-5	Ras	Cancer
KRAS-IN-5 (Compound Ex 6) is an orally active and selective inhibitor targeting *KRAS* mutants (including KRAS ^G12D, KRAS ^G12V, KRAS ^WT) with a GNE IC₅₀ value of 1.3 nM against KRAS ^G12D. KRAS-IN-5 blocks tumor cell proliferation by inhibiting KRAS-mediated signaling pathways (e.g., reducing ERK phosphorylation). KRAS-IN-5 is promising for research of KRAS mutation-related cancers, such as pancreatic cancer, colorectal cancer, lung cancer .

HY-151288

KRAS inhibitor-21	Ras	Cancer
KRAS inhibitor-21 (22b) is a KRAS G12C inhibitor with an IC₅₀ value of <0.01 μM. KRAS inhibitor-21 can be used in cancer research .

HY-RS07427

Kras Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Kras Rat Pre-designed siRNA Set A contains three designed siRNAs for Kras gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Kras Rat Pre-designed siRNA Set A Kras Rat Pre-designed siRNA Set A

HY-139911

KRAS G12D inhibitor 7	Ras	Cancer
KRAS G12D inhibitor 7 is a potent inhibitor of KRAS G12D (extracted from patent WO2021108683, compound 114) .

HY-RS07426

Kras Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Kras Mouse Pre-designed siRNA Set A contains three designed siRNAs for Kras gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Kras Mouse Pre-designed siRNA Set A Kras Mouse Pre-designed siRNA Set A

HY-139910

KRAS G12D inhibitor 6	Ras	Cancer
KRAS G12D inhibitor 6 is a potent inhibitor of KRAS G12D (extracted from patent WO2021108683A1, compound 112) .

HY-160445

KRAS G12D inhibitor 19	Ras	Cancer
KRAS G12D inhibitor 19 (Compound 7) is a KRAS G12D inhibitor. KRAS G12D inhibitor 19 can be used for the research of cancer .

HY-176419

KRAS inhibitor-42	Ras	Cancer
KRAS inhibitor-42 (compound 8) is a potent USP7 inhibitor. KRAS inhibitor-42 has high affinity against GDP-bound KRASG12D with a K_i of 2.7 μM .

HY-174851

KRAS G12C-IN-70	Ras	Cancer
KRAS G12C-IN-70 is a selective KRAS G12C mutant inhibitor. KRAS G12C-IN-70 blocks KRAS G12C-mediated downstream signaling pathways (e.g., RAF-MEK-ERK) and inhibits tumor cell proliferation. KRAS G12C-IN-70 is promising for research of KRAS G12C mutation-related tumors (such as non-small cell lung cancer, colorectal cancer) .

HY-143592

KRAS G12C inhibitor 39	Ras	Cancer
KRAS G12C inhibitor 39 is a potent inhibitor of KRAS G12C. KRas is a highly attractable target of the pharmaceutical industry for cancer research. KRAS G12C inhibitor 39 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2019099524A1, compound 494) .

HY-164315

KRAS G12C inhibitor 67	Ras	Cancer
KRAS G12C inhibitor 67 (example 35) is a KRAS G12C inhibitor that selectively inhibits the growth of many KRAS G12C mutant tumor cell lines .

HY-161236

KRAS ligand 4	Molecular Glues SOS1 Ras	Cancer
KRAS ligand 4 (compound 2) is a bifunctional molecular glue degrader based on SOS1. KRAS ligand 4 reduces downstream signaling markers pERK and pS6 and displays anti-additional activity in cells with multiple KRAS mutations .

HY-135864

KRAS inhibitor-6	Ras	Cancer
KRAS inhibitor-6 is a potent KRAS G12C inhibitor, extracted from patent WO2017087528A1, compound A .

HY-135865

KRAS inhibitor-7	Ras	Cancer
KRAS inhibitor-7 is a potent KRAS G12C inhibitor, extracted from patent WO2017087528A1, compound B .

HY-135866

KRAS inhibitor-8	Ras	Cancer
KRAS inhibitor-8 is a potent KRAS G12C inhibitor, extracted from patent WO2017087528A1, compound C .

HY-168056

KRAS ligand 5	Others	Others
KRAS ligand 5 is the target protein ligand for PROTAC K-Ras Degrader-3 (HY-168054). PROTAC K-Ras Degrader-3 can specifically degrade KRAS mutated proteins .

HY-161234

KRAS ligand 3	Ras	Cancer
KRAS ligand 3 (compound 1) is BTX-6654 target-binding ligand that can bind KRAS inhibitor and diaplay synergistic tumor growth inhibiton .

HY-148261

KRAS G12C inhibitor 56	Ras	Cancer
KRAS G12C inhibitor 56 (compound IC-6) is a potent SOS1 inhibitor with an IC₅₀ of 1.6 nM. KRAS G12C inhibitor 56 can be used in cancer research .

HY-142460

KRAS G12C inhibitor 28	Ras	Cancer
KRAS G12C inhibitor 28 is a KRAS G12C inhibitor with an IC₅₀ of 57 nM. KRAS G12C inhibitor 28 has antitumor effects (WO2021113595A1; Example 1) .

HY-144661

KRAS G12D inhibitor 14	Ras Apoptosis	Cancer
KRAS G12D inhibitor 14 is a potent KRAS G12D inhibitor with a K_D of 33 nM for binding to KRAS G12D protein. KRAS G12D inhibitor 14 decreases the active form of KRAS G12D (KRAS G12D-GTP) but not KRAS G13D .

HY-132980

Olomorasib KRAS G12C inhibitor 19	Ras	Cancer
Olomorasib is a potent inhibitor of KRAS G12C. Olomorasib significantly inhibits tumor growth (extracted from patent WO2021118877A1) .

HY-142458

KRAS G12C inhibitor 27	Ras	Cancer
KRAS G12C inhibitor 27 is a KRAS G12C inhibitor with antitumor effects (WO2021109737) .

HY-142457

KRAS G12C inhibitor 26	Ras	Cancer
KRAS G12C inhibitor 26 is a KRAS G12C inhibitor with antitumor effects (WO2021109737) .

HY-143588

KRAS G12C inhibitor 35	Ras	Cancer
KRAS G12C inhibitor 35 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 35 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent CN112920183A, compound 3) .

HY-143591

KRAS G12C inhibitor 38	Ras	Cancer
KRAS G12C inhibitor 38 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 38 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2021129820A1, compound 171) .

HY-143590

KRAS G12C inhibitor 37	Ras	Cancer
KRAS G12C inhibitor 37 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 37 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2018143315A1, compound 65) .

HY-143606

KRAS G12D inhibitor 12	Ras	Cancer
KRAS G12D inhibitor 12 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 12 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 134) .

HY-143594

KRAS G12C inhibitor 40	Ras	Cancer
KRAS G12C inhibitor 40 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 40 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2021129824A1, compound 70) .

HY-143604

KRAS G12D inhibitor 11	Ras	Cancer
KRAS G12D inhibitor 11 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 11 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 52) .

HY-143598

KRAS G12C inhibitor 42	Ras	Cancer
KRAS G12C inhibitor 42 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 42 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2020146613A1, compound 10) .

HY-143599

KRAS G12D inhibitor 8	Ras	Cancer
KRAS G12D inhibitor 8 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 8 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021107160A1, compound 2) .

HY-143607

KRAS G12D inhibitor 13	Ras	Cancer
KRAS G12D inhibitor 13 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 13 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 142) .

HY-143602

KRAS G12D inhibitor 9	Ras	Cancer
KRAS G12D inhibitor 9 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 9 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 20) .

HY-143596

KRAS G12C inhibitor 41	Ras	Cancer
KRAS G12C inhibitor 41 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 41 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2021129824A1, compound 121) .

HY-143603

KRAS G12D inhibitor 10	Ras	Cancer
KRAS G12D inhibitor 10 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 10 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 34) .

HY-162444

KRAS G12D inhibitor 22	Ras	Cancer
KRAS G12D inhibitor 22 (compound 6) is a inhibitor of *KRAS* mutation. KRAS G12D inhibitor 22 has high activity (IC₅₀＜100 nM), good selectivity and low toxicity.KRAS G12D inhibitor 22 can be used in breast cancer research .

HY-115880

KRAS G12D inhibitor 3	Ras	Cancer
KRAS G12D inhibitor 3 is a KRAS G12D inhibitor with an IC₅₀ of <500 nM. KRAS G12D inhibitor 3 has antitumor effects (WO2022002102A1; compound 146) . KRAS G12D inhibitor 3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-147595

KRAS G12D inhibitor 15	Ras	Cancer
KRAS G12D inhibitor 15 is a potent inhibitor of KRAS G12D. KRAS G12D inhibitor 15 has the potential for the research of various diseases or disorders, such as cancer or cancer metastasis (extracted from patent WO2022042630A1, compound 243) . KRAS G12D inhibitor 15 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-115880A

KRAS G12D inhibitor 3 TFA	Ras	Cancer
KRAS G12D inhibitor 3 TFA is a KRAS G12D inhibitor with an IC₅₀ of <500 nM. KRAS G12D inhibitor 3 TFA has antitumor effects (WO2022002102A1; compound 146) . KRAS G12D inhibitor 3 (TFA) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P3129

KRAS G13D peptide, 25 mer	Ras	Inflammation/Immunology Cancer
KRAS G13D peptide, 25 mer, a KRAS activating oncogene mutation peptide, is an immune potentiator extracted from patent WO2018144775A1. KRAS G13D peptide, 25 mer can be used to prepare KRAS vaccine .

HY-132979

KRAS G12C inhibitor 18	Ras	Cancer
KRAS G12C inhibitor 18 is a potent and orally active KRAS G12C inhibitor. Anti-tumor activities .

HY-156819

Zoldonrasib 1 Publications Verification RMC-9805; KRAS G12D inhibitor 18	Ras Apoptosis	Cancer
Zoldonrasib (RMC-9805) is a potent and orally active KRAS G12D inhibitor.Zoldonrasib induces apoptosis in KRAS G12D mutant cancer cells. Zoldonrasib has the potential for the research of KRAS G12D mutant cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0735

Phellodendrine chloride 1 Publications Verification	Alkaloids Structural Classification Phellodendron amurense Rupr. Classification of Application Fields Source classification Rutaceae Phenols Polyphenols Plants Isoquinoline Alkaloids Disease Research Fields Cancer	Autophagy
Phellodendrine chloride is a plant alkaloid found in Phellodendron amurense. Phellodendrine chloride suppresses the proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis . Phellodendrine chloride promotes autophagy by regulating the AMPK/mTOR pathway and reduce the intestinal damage of ulcerative colitis .

HY-N8387

Neogrifolin	Structural Classification Human Gut Microbiota Metabolites Microorganisms Source classification Phenols Polyphenols Endogenous metabolite	Ras
Neogrifolin is an inhibitor of *KRAS. Neogrifolin suppress KRAS* expression in human colon cancer cells. Neogrifolin has anti-cell viability activity against HeLa, SW480 and HT29 cells wih IC₅₀s of 24.3, 34.6, and 30.1 μM, respectively .

HY-120885

(+)-Oxanthromicin	Structural Classification Microorganisms Source classification Phenols Polyphenols	Ras
(+)-Oxanthromicin (Compound 1) mislocalizes the oncogenic mutant K-Ras from the plasma membrane of intact Madin-Darby canine kidney (MDCK) cells, and exhibits thereby antitumor efficacy .

HY-112541

21-Hydroxyoligomycin A	Structural Classification Microorganisms Macrolide Antibiotics Antibiotics Source classification	Ras Antibiotic
21-Hydroxyoligomycin A is a potent inhibitor of K-Ras PM localization with an IC₅₀ value of 4.82 nM. 21-Hydroxyoligomycin A has cytotoxicity and can be isolated from Streptomyces .

HY-N0735R

Phellodendrine chloride (Standard)	Alkaloids Structural Classification Phellodendron amurense Rupr. Source classification Rutaceae Phenols Polyphenols Plants Isoquinoline Alkaloids	Reference Standards Autophagy
Phellodendrine (chloride) (Standard) is the analytical standard of Phellodendrine (chloride). This product is intended for research and analytical applications. Phellodendrine chloride is a plant alkaloid found in Phellodendron amurense. Phellodendrine chloride suppresses the proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis . Phellodendrine chloride promotes autophagy by regulating the AMPK/mTOR pathway and reduce the intestinal damage of ulcerative colitis .

Cat. No.	Product Name	Chemical Structure

HY-157031S

KRASG12D-IN-2
KRASG12D-IN-2 (compound 28) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-157029S

KRASG12D-IN-1
KRASG12D-IN-1 (compound 22) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-114277S

Sotorasib-d7

Sotorasib-d₇ (AMG-510-d₇) is a deuterium-labeled Sotorasib (HY-114277). Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib leads to the regression of KRAS G12C‑mutated locally advanced or metastatic non‑small cell lung cancer (NSCLC) .

HY-160220S

KRAS inhibitor-23
KRAS inhibitor-23 (Isomer 2 of compound i) is a potent inhibitor of KRAS that plays an important role in cancer research .

HY-162445S

KRASG12D-IN-3-d3
pan-KRAS-IN-5-d₃ is deuterated labeled pan-KRAS-IN-5.

HY-114436S

MRTX-1257-d6
MRTX-1257-d₆ is the deuterium labeled MRTX-1257 (HY-114436). MRTX-1257 is a selective, irreversible, covalent and orally active KRAS G12C inhibitor, with an IC₅₀ of 900 pM for KRAS dependent ERK phosphorylation in H358 cells .

HY-114277S2

Sotorasib-d3
Sotorasib-d₃ (AMG-510-d₃) is deuterium labeled Sotorasib. Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib leads to the regression of KRAS G12C?mutated locally advanced or metastatic non?small cell lung cancer (NSCLC) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks